COVID-19治疗的教训:IDSA治疗指南专家组的批判性视角
本文基于IDSA COVID-19治疗指南专家组的观点,总结了疫情期间治疗试验(如SOLIDARITY、RECOVERY、ACCT-1)快速开展与数据传播的经验,指出在试验实施、结果传播与解读、监管指导方面仍存在关键不足,并提出了对未来新发传染病防控的启示。
要点
- 需在治疗试验中建立并标准化临床意义终点。
- 应针对特定人群和表型以最大化特定疗法的获益。
- 需建立快速关键数据审查与传播的标准流程,并明确EUA与BLA的证据标准。
核心结论
- COVID-19治疗试验快速产生数据支持有效疗法,但试验实施、结果传播与解读、监管指导仍存关键不足,其教训对当前疫情和未来新发传染病均有启示。
研究设计与样本
- 本文为IDSA COVID-19治疗指南专家组的观点总结,基于SOLIDARITY、RECOVERY、ACCT-1等关键试验的经验。
主要发现
- 关键试验快速开展并传播数据以支持有效疗法,但在试验实施、结果传播与解读、监管指导方面存在不足。
关键数值与推荐
- 需在治疗试验中建立并标准化临床意义终点,并针对特定人群和表型以最大化特定疗法获益。
- 应建立快速关键数据审查与传播的标准流程以确保科学诚信。
- 应明确紧急使用授权(EUA)和生物制品许可申请(BLA)所需的证据标准,并维持疫情下快速试验的基础设施。
临床怎么用
- 临床医生应关注治疗试验的临床意义终点和特定人群获益证据,并理解监管证据标准对疗法可及性的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite the challenges of the pandemic, there has been substantial progress with coronavirus disease 2019 (COVID-19) therapies. Pivotal COVID-19 trials like SOLIDARITY, RECOVERY, and ACCT-1 were rapidly conducted and data disseminated to support effective therapies. However, critical shortcomings remain on trial conduct, dissemination and interpretation of study results, and regulatory guidance in pandemic settings. The lessons that we learned have implications for both the current pandemic and future emerging infectious diseases. There is a need for establishing and standardizing clinical meaningful outcomes in therapeutic trials and for targeting defined populations and phenotypes that will most benefit from specific therapies. Standardized processes should be established for rapid and critical data review and dissemination to ensure scientific integrity. Clarity around the evidence standards needed for issuance of both emergency use authorization (EUA) and biologic license application (BLA) should be established and an infrastructure for executing rapid trials in epidemic settings maintained.
引用
- Bhimraj A, Morgan RL, Shumaker AH, et al. Lessons Learned from Coronavirus Disease 2019 (COVID-19) Therapies: Critical Perspectives From the Infectious Diseases Society of America (IDSA) COVID-19 Treatment Guideline Panel. Clin Infect Dis. 2022. PMID: 34668008. doi:10.1093/cid/ciab882
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。